创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

WANG He, WANG Song, LI Fangyin. Current Status and Prospects of Clinical Anti-prostate Cancer Nuclear Receptor-Targeted Drugs[J]. Progress in Pharmaceutical Sciences, 2023, 47(8): 608-616. DOI: 10.20053/j.issn1001-5094.2023.08.005
Citation: WANG He, WANG Song, LI Fangyin. Current Status and Prospects of Clinical Anti-prostate Cancer Nuclear Receptor-Targeted Drugs[J]. Progress in Pharmaceutical Sciences, 2023, 47(8): 608-616. DOI: 10.20053/j.issn1001-5094.2023.08.005

Current Status and Prospects of Clinical Anti-prostate Cancer Nuclear Receptor-Targeted Drugs

  • Prostate cancer is one of the most common malignancies in males and one of the leading causes of male mortality.Over the past few decades, the treatment landscape of prostate cancer has undergone significant changes.Traditional treatment modalities include surgery, radiotherapy, and hormonotherapy.However, with the in-depth study of the pathogenesis of prostate cancer, nuclear receptortargeted drugs have emerged as an important component in the treatment of prostate cancer.This article reviews the nuclear receptors within prostate cancer as well as the currently developed anti-prostate cancer nuclear receptor-targeted drugs and their resistance mechanisms and safety, along with a prospect of the future development of such drugs.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return